NeuBase to Present at the Jefferies London Healthcare Conference
NeuBase Therapeutics (Nasdaq: NBSE) will present a corporate overview at the Jefferies London Healthcare Conference on November 17, 2021, from 8:40 a.m. to 9:15 a.m. GMT. CEO Dietrich A. Stephan, Ph.D., will discuss the company's innovative precision genetic medicines aimed at addressing genetic diseases at their source. NeuBase's therapies focus on silencing disease-causing genetic mutations, with initial applications in neuromuscular, neurological, and oncologic disorders. For more information, visit NeuBase Therapeutics.
- None.
- None.
PITTSBURGH, Nov. 03, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, announced today that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will present in person a corporate overview at the Jefferies London Healthcare Conference being held November 16 - 18.
| Jefferies London Healthcare Conference | ||
| Date: | Wednesday, November 17 | |
| Time: | 8:40 a.m. – 9:15 a.m. GMT | |
| Location: | Webcast Link | |
About NeuBase Therapeutics
NeuBase is accelerating the genetic revolution by developing a new class of precision genetic medicines which can be designed to increase, decrease, or change gene function, as appropriate, to resolve genetic defects that drive disease. NeuBase’s targeted PATrOL™ therapies are centered around its proprietary drug scaffold to address genetic diseases at the DNA or RNA level by combining the highly targeted approach of traditional genetic therapies with the broad organ distribution capabilities of small molecules. With an initial focus on silencing disease-causing mutations in debilitating neuromuscular, neurological and oncologic disorders, NeuBase is committed to redefining medicine for the millions of patients with both common and rare conditions. To learn more, visit www.neubasetherapeutics.com.
Investor Contact:
Daniel Ferry
LifeSci Advisors
+1 (617) 430-7576
daniel@lifesciadvisors.com
NeuBase Media Information:
Jessica Yingling, Ph.D.
Little Dog Communications Inc.
+1 (858) 344-8091
jessica@litldog.com
FAQ
When is NeuBase Therapeutics presenting at the Jefferies London Healthcare Conference?
Who is the CEO of NeuBase Therapeutics?
What is the focus of NeuBase Therapeutics' therapies?
Where can I find the webcast link for the NeuBase presentation?
What type of disorders does NeuBase Therapeutics aim to address?
